In the news

Posts tagged UK CDMO

Hired and retired: New appointments in the biopharma industry

Hired and retired: New appointments in the biopharma industry

Florence BuchananDecember 2, 2022CDMO, UK CDMO, ViroCell, gene therapy, cell and gene therapies, cell therapy, viral vector, viral vectors, New hires, Nick Maishman

ViroCell strengthens senior management team with appointment of Nick Maishman as COO

ViroCell strengthens senior management team with appointment of Nick Maishman as COO

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).

ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

In the NewsFlorence BuchananNovember 22, 2022viral vectors, UK CDMO, CDMO, gene therapy, cell therapy, clinical trials, cell and gene therapies, Nick Maishman, ViroCell, Pharmiweb.com

ViroCell Strengthens Senior Management Team with Appointment of Nick Maishman as COO

ViroCell Strengthens Senior Management Team with Appointment of Nick Maishman as COO

ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (COO).

ViroCell, an innovation-driven Contract Development and Manufacturing Organisation, is today addressing the global viral vector supply-demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene-modified cells for clinical trials. ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

In the NewsFlorence BuchananNovember 22, 2022UK CDMO, CDMO, gene therapy, cell therapy, cell and gene therapies, clinical trials, Nick Maishman, Pharmtech Focus, viral vectors

ViroCell names Susan Nichols as CBO

ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).

The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors…

In the NewsFlorence BuchananSeptember 20, 2022UK CDMO, CDMO, gene therapy, cell therapy, cell and gene therapies, clinical trials, viral vectors, Susan B Nichols, ViroCell, The Pharma Letter

ViroCell Announces the Appointment of Susan B. Nichols as CBO

ViroCell Announces the Appointment of Susan B. Nichols as CBO

ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

In the NewsFlorence BuchananSeptember 20, 2022UK CDMO, gene therapy, cell therapy, ViroCell, Pharmtech Focus, clinical trials, cell and gene therapies, CDMO, Susan B Nichols, viral vectors

Gene therapy ‘factory’ to save children

Gene therapy ‘factory’ to save children

A new “factory” that will produce benign viruses for Great Ormond Street Hospital is expected to accelerate the development of life-saving gene therapy drugs.

The facility, which is based in the hospital and operated by the biotech company ViroCell Biologics, will more than double Britain’s capacity to manufacture a key type of gene therapy.

Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

ViroCell Biologics confirms a new agreement to address the worldwide viral vector market for clinical trials.

Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

Great Ormond Street Hospital (GOSH) has partnered with manufacturer ViroCell Biologics in an effort to address the global viral vector manufacturing bottleneck for clinical trials.

In the NewsFlorence BuchananOctober 11, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, European Pharmaceutical Manufacturer, UK CDMO, ViroCell, Matthew Shaw, CEO at Great Ormond Street Hospital

ViroCell and Great Ormond Street Hospital for Children address viral vector manufacturing bottleneck

ViroCell and Great Ormond Street Hospital for Children address viral vector manufacturing bottleneck

As part of the partnership, ViroCell will more than double the UK’s lentivirus vector manufacturing capacity for clinical trials in 2022 and become the first UK CDMO to be able to deliver AAV vectors to the cell and gene therapy markets.

In the NewsFlorence BuchananOctober 2, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Health Newest, UK CDMO, John W. Hadden II, Farzin Farzaneh

ViroCell Biologics announces pivotal partnership with Great Ormond Street

ViroCell Biologics announces pivotal partnership with Great Ormond Street

Innovation-driven viral vector manufacturer, ViroCell Biologics, and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), have announced a new partnership that aims to dislodge the gene and cell therapy bottleneck.

In the NewsFlorence BuchananSeptember 28, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Pharmafile, UK CDMO, Matthew Shaw, CEO at GOSH, Great Ormond Street Hospital

ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and Great Ormond Street Hospital (GOSH) partner to tackle the viral vector manufacturing bottleneck for clinical trials.

In the NewsFlorence BuchananSeptember 28, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, UK CDMO, ViroCell, Great Ormond Street Hospital, European Pharmaceutical Review, EPR

ViroCell Biologics announces pivotal partnership with Great Ormond Street

ViroCell Biologics announces pivotal partnership with Great Ormond Street

In the NewsFlorence BuchananSeptember 28, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, UK CDMO

ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and Great Ormond Street Hospital for Children (GOSH) have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

In the NewsFlorence BuchananSeptember 28, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Biopharma Curated, UK CDMO, Great Ormond Street Hospital, Virocell

Partners aim to remove clinical trials bottleneck

Partners aim to remove clinical trials bottleneck

Life sciences firm ViroCell Biologics is working in partnership with Great Ormond Street Hospital (GOSH) to help alleviate a major barrier to progress in clinical trials.

In the NewsFlorence BuchananSeptember 28, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, cell therapy, gene therapy, Health Tech World, UK CDMO, vector design, John W. Hadden II, Farzin Farzaneh

ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

In the NewsFlorence BuchananSeptember 28, 2021CDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, cell therapy, gene therapy, UK CDMO, NHS Foundation Trust, Great Ormond Street Hospital, vector design, Pharmtech Focus

ViroCell Adds J. David Enloe And Dr. Martin Pule To Its Board Of Directors

ViroCell Adds J. David Enloe And Dr. Martin Pule To Its Board Of Directors

ViroCell Adds J. David Enloe And Dr. Martin Pule To Its Board Of Directors.

In the NewsFlorence BuchananSeptember 6, 2021CDMO, ViroCell Board of Directors, Scientific Advisory Board, J. David Enloe, Martin Pule, Life Sciences Review, UK CDMO, viral vectors, vector design

ViroCell Announces new Board appointments

ViroCell Announces new Board appointments

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.

ViroCell Announces New Board Appointments

ViroCell Announces New Board Appointments

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of J. David Enloe, Jr. to its Board of Directors and Martin Pule, MD, PhD to its Scientific Advisory Board, both leaders in their respective fields.

Tech News: ViroCell Biologics

Tech News: ViroCell Biologics

ViroCell Biologics, the UK’s first clinical trial-focused viral vector manufacturer, has officially launched.

It aims to be the supplier of choice for viral vectors and gene-modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials.

In the NewsFlorence BuchananJune 3, 2021CDMO, clinical trials, viral vectors, cell and gene therapies, The Biomedical Scientist, vector design, gene therapy, cell therapy, CGT, UK CDMO, Farzin Farzaneh, King's College London, viral vector